ストックスクリーナーアプリを入手
0.8793
1.72%
0.0149
アフターアワーズ：
.88
0.0007
+0.08%
前日終値:
$0.8644
開ける：
$0.92
24時間の取引高:
399.11K
Relative Volume:
0.98
時価総額：
$171.14M
収益：
$8.95M
当期純損益:
$-21.49M
株価収益率:
-6.7638
EPS:
-0.13
ネットキャッシュフロー:
$-29.24M
1週間 パフォーマンス:
-6.85%
1か月 パフォーマンス:
-3.09%
6か月 パフォーマンス:
-18.58%
1年 パフォーマンス:
-7.44%
1日の値動き範囲:
$0.867
$0.9286
1週間の範囲:
$0.8001
$0.97
52週間の値動き範囲:
$0.7665
$1.61
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
名前
Lineage Cell Therapeutics Inc
セクター
電話
510-871-4188
住所
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LCTX | 0.8793 | 171.14M | 8.95M | -21.49M | -29.24M | -0.13 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-14 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Noble Capital Markets | Outperform |
| 2021-03-31 | 開始されました | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highl - GuruFocus.com
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Lineage Cell: Q3 Earnings Snapshot - Houston Chronicle
Lineage Cell Therapeutics Reports Q3 2024 Highlights - TipRanks
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings: EPS of -$0.02, Revenue Surges to $3.8M, Beating Estimates - GuruFocus.com
Lineage Cell Therapeutics reports Q3 EPS (2c), consensus (3c) - TipRanks
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Lineage Cell Therapeutics's Earnings Outlook - Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - BioSpace
Lineage Cell Therapeutics to Report Q3 2024 Earnings on November 14 | LCTX Stock News - StockTitan
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit - Business Wire
Dendritic Cell Cancer Vaccine Immunotherapy Market Growing Rapidly by-Lineage Cell Therapeutics, AVAX Technologies, DCPr – IndiaPolitics.com - IndiaPolitics.com
Lineage Cell Therapeutics Inc [LCTX] Shares Fall -3.95 % on Thursday - Knox Daily
Lineage Cell Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing Lineage Cell Therapeutics Inc (LCTX)’s Performance - The Dwinnex
Lineage Looking to Restore Sight, Hearing, Movement - San Diego Business Journal
Allogeneic Stem Cells Market on Track for Strong Growth by 2031 | - openPR
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ... - Yahoo Finance
What Makes Lineage Cell (LCTX) a New Buy Stock - Yahoo Finance
ORBCOMM joins Move to -15°C coalition to promote cold chain sustainability - GlobeNewswire Inc.
Are Smart Investors Making the Right Decision? Lineage Cell Therapeutics Inc (LCTX) - SETE News
Baird maintains Outperform rating on Lineage Cell shares - Investing.com India
Understanding the Risks of Investing in Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Market Insights: Lineage Cell Therapeutics Inc (LCTX)’s Notable Drop of -1.60, Closing at 0.91 - The Dwinnex
Have you been able to find a good deal on Lineage Cell Therapeutics Inc’s shares? - US Post News
Logos Global Management LP Has $4.69 Million Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
LCTXLineage Cell Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium - Business Wire
Raffles Associates LP Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics Inc [LCTX] Investment Guide: What You Need to Know - Knox Daily
Global Autologous Cell Therapy Product Market Projected to Reach USD 40.77 Billion by 2032 with a 16.9% CAGR - 대구포스트
Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic
Lineage Cell Therapeutics Reports Successful Preclinical Results for Cell-Based Therapy for Hearing Loss - The Hearing Review
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop - StockTitan
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance - Business Wire
A Guide To The Risks Of Investing In Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Autologous Cell Therapy Product Market is Estimated to Reach USD 40.77 Billion By 2032 | Vantage Market Research - 대구포스트
Lineage Cell Therapeutics Inc [LCTX] Records 200-Day SMA of $1.0619 - Knox Daily
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Significant Growth in Short Interest - MarketBeat
Allogeneic Stem Cells Market to Witness Huge Growth by 2031 - openPR
Lineage Cell Therapeutics Inc (LCTX) gets rating Initiated from Craig Hallum - Knox Daily
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Coverage Initiated by Analysts at Craig Hallum - Defense World
Lineage Cell Therapeutics stock upgraded to buy on OpRegen potential - Investing.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Lineage Cell Therapeutics CFO buys $9,345 in company stock - Investing.com
Lineage Cell Therapeutics CFO buys $9,345 in company stock By Investing.com - Investing.com UK
Lineage Cell Therapeutics Inc (LCTX) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):